Former unicorn genetics startup Human Longevity loses its horn
The company's valuation has declined 80 percent, from a $1.6 billion peak to $310 million, according to The Wall Street Journal.
Human Longevity accuses its founder Craig Venter of stealing trade secrets
Genomic sequencing legend Craig Venter now stands accused of stealing trade secrets and attempting to poach employees by the very company he founded.
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Venter steps down as CEO of Human Longevity
J. Craig Venter will step down as CEO of his ambitious genomics-driven biotech Human Longevity, effective January 9.